Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease

Uri Kopylov, Greg Rosenfeld, Brian Bressler, Ernest Seidman

Research output: Contribution to journalReview articlepeer-review

Abstract

Diagnosis and monitoring of inflammatory bowel diseases rely on clinical, endoscopic, and radiologic parameters. Inflammatory biomarkers have been investigated as a surrogate marker for endoscopic diagnosis of inflammatory activity. Fecal inflammatory biomarkers such as calprotectin and lactoferrin are direct products of bowel inflammation and provide an accurate and noninvasive diagnostic and monitoring modality for Crohn's disease and ulcerative colitis. This report contains an overview of the currently existing literature pertaining to clinical implications of fecal biomarkers for diagnosis, monitoring, and prediction of outcomes of inflammatory bowel disease.

Original languageEnglish
Pages (from-to)742-756
Number of pages15
JournalInflammatory Bowel Diseases
Volume20
Issue number4
DOIs
StatePublished - Apr 2014
Externally publishedYes

Keywords

  • C-reactive protein
  • Crohn's disease
  • Fecal biomarkers
  • Fecal calprotectin
  • Lactoferrin
  • Ulcerative colitis

Fingerprint

Dive into the research topics of 'Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this